EGFR and non-small cell lung carcinoma: Over 60% of NSCLC patients express EGFR and tyrosine kinase inhibitors (TKIs) targeting the kinase domain of EGFR are clinically effective in NSCLC patients harboring activating mutations in the tyrosine kinase domain of the EGFR gene43.